Project: A novel inhibitor to prevent uncontrolled bleedings in anticoagulant users

Acronym DOAC-STOP (Reference Number: 10859)
Duration 01/04/2017
Project Topic DOAC-STOP aims to develop PseudoXa, a biological for the instantaneous restoration of blood clotting activity in patients with major bleedings as a result of blood thinners. PseudoXa will be produced and the preclinical efficacy, pharmacokinetics (PK), and toxicity (TOX) of PseudoXa will be determined in vitro and in vivo. The end result will be a completed preclinical study dossier for PseudoXa. After the project, clinical phase development will be initiated.
Network Eurostars 2
Call Eurostars Cut-Off 6

Project partner

Number Name Role Country
1 VarmX B.V. Coordinator Netherlands
2 Adlego Biomedical AB Partner Sweden
3 Northwick Park Institute for Medical Research Partner United Kingdom
4 Leiden University Medical Center Partner Netherlands